Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers
BNT164-01
Phase 1 other active
Quick answer
Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers for Tuberculosis is a Phase 1 program (other) at BioNTech Manufacturing GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioNTech Manufacturing GmbH
- Indication
- Tuberculosis
- Phase
- Phase 1
- Modality
- other
- Status
- active